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ABSTRACT 
 
The Differential Effects of Buprenorphine and Methadone on Adolescent Mice (May 2013) 
 
Joseph William Barwatt 
Institute for  
Neuroscience 
Texas A&M University 
 
 
Research Advisor: Dr. Shoshana Eitan 
Department of  
Psychology 
Texas A&M Institute for Neuroscience 
 
 
This study focuses on understanding the consequences of administering opioid maintenance 
drugs, such as buprenorphine and methadone, on the adolescent brain. This is because that there 
are growing needs to treat opioid dependence and addiction in adolescents and there is a lack of 
studies that aim at explaining the effects of opioid maintenance drugs on the still-developing 
adolescent brain. The goal of this study is to enable physicians to conduct a science-based risk 
assessment on the proper use of these treatments for that age group.  A recent study conducted in 
our lab has indicated potential risks in chronic exposure to certain opioids, specifically, morphine 
during adolescence.  Morphine exposure was observed to change the signaling of D2/D3 
dopamine receptors in adolescent mice.  The D2/D3 dopamine receptor may mediate long-term 
mental changes in adolescents, specifically changes linked to mood and psychotic disorders.  
Thus, this study examined whether buprenorphine and methadone alter the responses of the 
D2/D3 dopamine receptors differently in an adolescent population. Adolescent mice were orally 
administered buprenorphine, methadone, or saline once daily for 6 days. Two hours or three days 
later, the mice were tested for their locomotor response to quinpirole, a D2/D3 dopamine 
receptor agonist. Buprenorphine-treated adolescent mice showed a similar response to that of the 
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drug-naïve (saline-injected) group in their response to quinpirole. In contrast, an enhanced 
response was observed in methadone-treated adolescent animals. This effect was significantly 
higher two hours following the final dose of methadone, as compared to three days afterwards. 
As shown in this study, methadone exposure greatly disturbs the D2/D3 receptor’s signaling.  
This indicates that care should be taken when administering methadone to adolescents for 
addiction therapies as well as pain management. In contrast to methadone, buprenorphine 
appears to disrupt the D2/D3 dopamine receptor signaling in adolescents less. Therefore, this 
study may confirm that exposure to different opioids carries different risks, specifically in an 
adolescent population.  
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CHAPTER I 
 
INTRODUCTION 
 
The abuse of drugs, specifically opioids, is becoming more prevalent in adolescent populations.   
Next to marijuana, opioids are the most common form of illicit drug use in the United States1.   
Furthermore, the nonmedical use of pain relievers has shown to be more prevalent than the 
nonmedical use of stimulants, sedatives, and tranquilizers2.  These pain relievers are almost 
invariably an opioid.  Because of this, understanding the mechanism of action as well as 
developing ways to combat the risks associated with the use of opioids is becoming an important 
area for study, specifically when approaching adolescent populations.    
 
Currently, there is a small amount of research on how opioids differentially affect adults versus 
adolescents.   What our recent research has attempted to highlight is the fact that there are 
differences in how opioids affect adolescents in comparison to adults and the fact that there are 
varying effects between different opioids on these populations.  When considering neural 
activity, there may be many factors that contribute to this fact, but the continual development of 
the adolescent brain is one of the most important3.  In any case, it is appropriate to suggest that 
there are differences in how opioids act in each population, and that different opioids carry 
differing effects due to their varying molecular profiles4.  Furthermore, how we go about treating 
drug-dependence in these two populations should be carefully approached.   
 
In support of these hypotheses, we recently observed that morphine differentially alters the 
responses of the D2/D3 dopamine receptors in adults and adolescents.  
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Following repeated exposure to morphine, we found that adolescents experienced an intensified 
response upon exposure to a D2/D3 dopamine receptor agonist, a compound that increases the 
activity of this receptor system5.  Morphine altered the response of the D2/D3 dopamine 
receptors in adults, but to a significantly less extent than the response observed in adolescents. 
 
Although this effect might possibly be seen in other receptor-signaling pathways, our focus on 
the D2/D3 receptor is anchored in its implications in mental health and mediation of mood and 
psychotic disorders such as schizophrenia, depression, and bipolar disorder6.  Given there are 
differences in the actions of different drugs on this system, as well as differences amongst adults 
and adolescents in terms of the actions of these drugs, value can be found in a study that can 
determine the side-effects/risks associated with opioids in each population on this D2/D3 
receptor-signaling system.  Especially when considering how important the D2/D3 receptor-
signaling system is to mental status. 
 
Buprenorphine and methadone are primarily known for their use as maintenance treatments in 
human opioid addiction therapy, mainly for adults. However, with restriction and limitation, 
these drugs are also used for adolescents.  In addition, buprenorphine and methadone are also 
used for pain management in both populations and methadone is becoming a commonly abused 
opioid by adolescents3,7.  Both drugs have been shown to be effective in treating addiction. 
However, many warnings have been issued in association with the use of them.  Surprisingly, 
there are a very small amount of studies that focus on the specific dangers associated with the 
two drugs, especially for adolescents.  Given the importance of D2/D3 dopamine receptors to 
mental health, this study has focused on the differing effects of methadone and buprenorphine on 
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the D2/D3 receptor-signaling pathway. Moreover, because there is a gap in the literature on the 
effects of opioids on adolescent populations, we chose to focus our research on this population.  
Lastly, to increase the clinical relevancy of this research, the mice were administered the drugs 
via gavage injection (oral).  This is because humans are most commonly administered 
pain/maintenance treatments via oral administration (pills).  The knowledge acquired in these 
studies will hopefully assist psychiatrists and other physicians in developing a safer treatment 
regimen for adolescents receiving both addiction maintenance therapy and pain management 
therapy.  
 
In this study we examined the effects of buprenorphine and methadone on the D2/D3 dopamine 
receptor-signaling in adolescent mice.  We used similar methodology to those used in our 
previous study with morphine.  In the first experiment, adolescent mice were administered once 
daily for six days with one of three different doses of methadone (25, 50, or 100 mg/kg) or 
buprenorphine (.1, .2, .4 mg/kg) or a saline solution.  Three days later the mice were examined 
for their locomotor response to quinpirole, a D2/D3 receptor agonist.  In the second experiment, 
mice were administered similarly with either 50 mg/kg methadone, 0.2 mg/kg buprenorphine or 
saline and their response to quinpirole was tested 2 hours after the last injection.  This 
experiment was done in order to determine whether the effects of the opioids on D2/D3 
dopamine receptor-signaling are due to the withdrawal effects or the actual drugs themselves.  In 
the third experiment, we examined the blood plasma levels of methadone and buprenorphine 
after six days of administration to confirm that the drug levels are within the relevant range when 
compared to humans receiving therapeutic doses of each drug.  
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CHAPTER II 
 
MATERIALS AND METHODS 
Animals 
All procedures were conducted in accordance with the National Institutes of Health (NIH) Guide 
for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care 
and Use Committee. Adolescent male C57BL/6 mice were purchased from Harlan Labs in 
Houston, TX.  Mice were housed in groups of 4 and supplied with rodent food and water ad lib.  
The vivarium was temperature controlled (21 ± °C) with a 12 h/12 h light/dark cycle for 
approximately one week prior to treatment, allowing for acclimation of the mice to the 
environment. Mice were determined to be in the adolescent phase based on studies by Spear and 
colleagues, which described the three developmental stages for rodents from weaning to 
adulthood. In accordance with these studies, mice were purchased at postnatal day 22 (PND 22).  
They were allowed to acclimate to the vivarium until the age of PND 28.  Injections of 
methadone, buprenorphine, or saline began on PND 28, and behavioral testing was performed on 
PND 33 or 36.  Accordingly, mice were injected during late prepubescent period and were tested 
during their mid-adolescent period.   
 
Treatment regimen 
Adolescent mice (n=13-31 per experimental group) were administered buprenorphine (0.1, 0.2, 
or 0.4 mg/kg), methadone (25, 50, or 100 mg/kg) or saline once daily for six days via gavage 
injection.  Methadone and Buprenorphine were purchased from Sigma-Aldrich Chemicals (St 
Louis, MO).  Doses were given to represent plasma levels that are representative of a human 
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therapeutic dose8,9,10.  The dose was selected in accordance with existing literature on the 
pharmacokinetics of the selected drugs in mice11.  
 
Locomotion testing 
8 activity chambers were each equipped with optical beam activity monitors (Model RXYZCM-
16; Accusan Instruments, Columbus, OH, USA) and were used to assess the activity of the mice.   
The chambers consisted of a 40 X 40 X 30.5 cm acrylic cage with the optical beam monitors 
positioned around this cage.  This system of chambers was set up in a sound-proof room 
equipped with a 40 dB white noise producer operating at all times when mice were present in the 
room.  When mice are present in the chambers, a multiplexor-analyzer tracks the mice by 
monitoring the interruption of beams from the optical beam monitors.  The position of the mice 
in the acrylic chambers is updated every 10 ms using a real-time computerized conversion 
system.  Activity measurements are obtained from the computerized sorting of the data. 
 
Two-hour withdrawal procedure 
Following the last injection of buprenorphine, methadone, or saline solution, the mice were left 
in the vivarium for 1 hour.  Immediately following, the mice were moved to the activity room for 
a 30 minute habituation period.  The mice were then placed, one per chamber, into the center of 
the activity chambers, and a 30 minute baseline period was recorded.  Once the baseline period 
was complete, the mice were injected via IP with either quinpirole (10 mg/kg) or a vehicle 
solution and were placed back into their respective chambers for a 120 minute locomotor 
session.  Immediately after this session, mice were placed back into their cage and moved out of 
the activity room.  Using pentobarbital (100 mg/kg) via IP injection, the mice were euthanized.  
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After euthanasia, the brains were taken and frozen by placing them in a plastic container and 
setting the container into a mixture of dry ice and acetone.  Once all of the brains were removed 
and completely frozen, they were preserved at -80°C. 
 
Three day withdrawal procedure 
Following the last administration of buprenorphine, methadone, or saline, mice were left in the 
vivarium for 3 days.  On the 3rd day, the mice were moved into the activity room for a 30 minute 
habituation period.  All procedures from this point are identical to the two hour withdrawal 
procedure described above. 
 
Plasma levels of buprenorphine and methadone 
As described above, mice (n=8-9 per group) were administered 0.2 mg/kg buprenorphine or 50 
mg/kg methadone for six days.  Two, 6, or 24 hours following final treatment of drug, mice were 
anesthetized using pentobarbital (100 mg/kg) via intraperitoneal injection.  Immediately 
following, blood was collected via intra-cardiac puncture with syringes lined with heparin.  
Plasma was immediately separated via centrifugation (15 min, 1000g, 4°C) and stored at -80°C.  
Buprenorphine and methadone levels from the acquired plasma was determined using an ELISA 
Kit purchased from Neogen Corporation (St. Joseph, MI). 
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Data analysis 
Total distance traveled (cm) scores for each mouse during the 120 minute post-vehicle or post-
quinpirole period were normalized to the total distance traveled (cm) during the 30 minute 
baseline activity using the formula: [total distance traveled post-vehicle or post-quinpirole/total 
distance traveled (cm) during baseline] X 100.  Data for between-subjects factor of treatment 
was analyzed for the normalized total distance traveled scores (% from baseline) during the 120 
minutes post-vehicle or post-quinpirole using the Univariate Analysis of Variance (SPSS 
Statistics 18, Somers, NY).  Additional temporal analysis of a factorial consisting of between-
group factors of treatment (buprenorphine, methadone, or saline) and within-group factor of time 
(1-120 minutes post-injection period summed in 5 minute intervals) was also computed.  For this 
analysis, for each mouse the score of the last 5-minute interval prior to the vehicle or quinpirole 
injections (baseline) was used to normalize the data.  Post-hoc contrasts between each treatment 
group were computed using Bonferroni post-hoc procedure.  Differences with p-values of less 
than 0.05 were deemed statistically significant.  Results are shown as mean +/- SEM. 
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CHAPTER III 
RESULTS 
Experiment I: Three-day withdrawal 
 
Total distance traveled post-vehicle 
When mice were administered vehicle immediately prior to the 120 minute test period, a Univariate	   Analysis	   of	   Variance	   revealed	   no	   significant	   differences	   in	   locomotor	   activity	  levels	  between	  drug-­‐naïve	  mice	  and	  mice	  administered	  the	  various	  doses	  of	  buprenorphine	  and	  methadone	  (F(6,	  81)=0.73,	  p>0.05,	  n.s.)	  (Shown	  in	  Figure	  1a).	  	  	  	  
	  
Total	  distance	  traveled	  post-­‐quinpirole	  When	  mice	  were	  administered	  quinpirole	  immediately	  prior	  to	  the	  120	  minute	  locomotor	  test	   period,	   a	   Univariate	   Analysis	   of	   Variance	   revealed	   significant	   differences	   in	   activity	  levels	  between	  mice	  treated	  with	  the	  various	  drugs	  (F(6,	  117)=4.38,	  p<0.0001).	   	  Post	  hoc	  comparison	  revealed	  no	  differences	  in	  quinpirole-­‐induced	  suppression	  of	  activity	  between	  the	   saline-­‐injected	   mice	   and	   mice	   treated	   with	   0.1,	   0.2,	   and	   0.4	   mg/kg	   buprenorphine.	  	  Significant	  differences	  were	  revealed	  between	  saline-­‐injected	  mice	  	  (drug-­‐naïve)	  and	  mice	  treated	  with	  25,	  50,	  and	  100	  mg/kg	  methadone	  (p<0.05).	  	  The	  mice	  were	  observed	  to	  have	  less	   of	   a	   decrease	   in	   activity	   when	   administered	   quinpirole	   in	   contrast	   with	   the	   saline-­‐injected	  (drug-­‐naïve)	  mice.	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Temporal	  analysis	  post-­‐vehicle	  Temporal	  analyses	  were	  computed	  by	  taking	  5	  minute	   intervals	  of	  the	  120	  minutes	  post-­‐vehicle	   injection	   and	   calculating	   distanced	   traveled	   scores	   for	   each	   interval.	   Figure	   2a	  presents	   the	   results	   for	   the	   buprenorphine-­‐treated	   animals.	   Two-­‐way	   repeated-­‐measure	  ANOVA	   revealed	   a	   main	   effect	   of	   time	   (F(23,	   1058)=7.13,	   p<0.0001),	   but	   no	   significant	  main	  effect	  of	  treatment	  (F(3,	  46)=0.14,	  p>0.05,	  n.s.)	  and	  no	  significant	  interaction	  between	  treatment	   and	   time	   (F(69,	   1058)=1.06,	   p>0.05,	   n.s.).	   Activity	   levels	   declined	   as	   the	   test	  period	   proceeded.	   	   However,	   there	   were	   no	   significant	   differences	   in	   activity	   levels	  between	   drug-­‐naïve	   mice	   and	   mice	   administered	   0.1,	   0.2,	   or	   0.4	   mg/kg	   buprenorphine.	  	  Figure	   2b	   presents	   the	   results	   for	   the	   methadone-­‐treated	   animals.	   Two-­‐way	   repeated-­‐measure	   ANOVA	   revealed	   a	   main	   effect	   of	   time	   (F(23,	   1058)=5.78,	   p<0.0001),	   but	   no	  significant	   main	   effect	   of	   treatment	   (F(3,	   46)=0.12,	   p>0.05,	   n.s.),	   and	   no	   significant	  interaction	   between	   treatment	   and	   time	   (F(69,	   1058)=1.08,	   p>0.05,	   n.s.).	   Activity	   levels	  were	  observed	  to	  decrease	  as	  the	  test	  period	  proceeded.	  However,	  as	  with	  buprenorphine,	  no	   differences	   in	   their	   activity	   levels	  were	   observed	   between	   drug-­‐naïve	  mice	   and	  mice	  administered	  25,	  50,	  or	  100	  mg/kg	  methadone.	  	  
Temporal	  analysis	  post-­‐quinpirole	  Figure	   2c	   presents	   the	   temporal	   analysis	   following	   quinpirole	   treatment	   for	   the	  buprenorphine	  treated	  animals.	  Two-­‐way	  repeated-­‐measure	  ANOVA	  revealed	  a	  main	  effect	  of	   time	   (F(23,	   1633)=13.37,	   p<0.0001),	   but	   no	   significant	  main	   effect	   of	   treatment	   (F(3,	  71)=1.68,	  p>0.05,	  n.s.),	   and	  no	   significant	   interaction	  between	   treatment	  and	   time	   (F(69,	  1633)=0.87,	   p>0.05,	   n.s.).	   Post	   hoc	   comparison	   revealed	   no	   differences	   in	   quinpirole-­‐12	  
	   	   	  	   	  
	  	  
induced	   attenuation	   of	   activity	   level	   between	   drug-­‐naïve	   mice	   (i.e.	   saline-­‐injected	  mice)	  and	   mice	   treated	   with	   the	   various	   doses	   of	   buprenorphine.	   	   	   Similar	   to	   the	   drug-­‐naïve	  animals,	  the	  buprenorphine	  treated	  animals	  showed	  a	  steady	  increase	  in	  locomotor	  activity	  starting	   at	   10	   minutes	   following	   buprenorphine	   administration,	   with	   the	   locomotor	  response	   peaking	   at	   25	   minutes.	   	   From	   the	   peak	   at	   25	   minutes,	   a	   steady	   decline	   in	  locomotor	  activity	  was	  observed	  followed	  by	  a	  very	  gradual	  increase	  in	  locomotor	  activity	  for	   the	   remainder	  of	   the	   session.	   	  At	   120	  minutes,	   the	  0.4	  mg/kg	  buprenorphine-­‐treated	  animals	   showed	   the	   greatest	   increase	   in	   locomotor	   activity	   while	   the	   0.2	   mg/kg	  buprenorphine-­‐treated	  animals	  showed	  the	  least	  increase	  in	  locomotor	  activity.	  However,	  no	  significant	  differences	  from	  saline-­‐injected	  control	  animals	  were	  observed	  at	  any	  of	  the	  time	  points.	  	  	  Figure	  2d	  presents	  the	  results	  for	  the	  temporal	  analysis	  following	  quinpirole	  treatment	  for	  the	  methadone-­‐treated	  animals.	  Two-­‐way	  repeated-­‐measure	  ANOVA	  revealed	  a	  main	  effect	  of	  time	  (F(23,	  1702)=21.37,	  p<0.0001),	  a	  main	  effect	  of	  treatment	  (F(3,	  74)=3.41,	  p<0.05),	  and	  a	  significant	  interaction	  between	  treatment	  and	  time	  (F(69,	  1702)=2.61,	  p<0.0001).	  In	  contrast	  to	  buprenorphine,	  significant	  differences	  in	  the	  locomotor	  response	  to	  quinpirole	  between	   drug-­‐naïve	   mice	   and	   mice	   treated	   with	   the	   various	   doses	   of	   methadone	   were	  observed	   in	   the	   5	  minute	   interval	   periods	   during	   the	   120	  minutes	   test	   period	   following	  administration	  of	  quinpirole	  (p<0.05).	  	  Specifically,	  each	  of	  the	  methadone-­‐treated	  animals	  showed	   a	   sharp	   increase	   in	   locomotor	   activity	   starting	   20	  minutes	   following	   quinpirole	  administration,	   with	   the	   locomotor	   response	   peaking	   at	   30	   minutes.	   	   Immediately	  13	  
	   	   	  	   	  
	  	  
following	   the	   peak	   of	   the	   locomotor	   response,	   a	   sharp	   decline	   was	   observed	   until	   40	  minutes	   following	   quinpirole	   administration.	   	   From	   40	   minutes	   following	   quinpirole	  administration	   until	   the	   remainder	   of	   the	   session,	   we	   observed	   a	   steady	   increase	   in	  locomotor	   activity	   for	   the	   methadone-­‐treated	   animals.	   	   At	   120	  minutes,	   the	   100	  mg/kg	  methadone-­‐treated	  animals	  showed	  the	  greatest	   increase	   in	   locomotor	  activity,	  while	   the	  25	  mg/kg	  methadone	  treated	  animals	  showed	  the	  least	  increase	  in	  locomotor	  activity.	  	  	  	  
Experiment	  II:	  	  Two-­‐hour	  withdrawal	  	  
	  
Total	  distance	  traveled	  post-­‐vehicle	  Figure	   3a	   presents	   the	   results	   for	   the	   total	   distance	   traveled	   scores	   (%	   from	   baseline)	  during	  the	  120	  minutes	   following	  treatment	  with	  vehicle.	  Univariate	  Analysis	  of	  Variance	  revealed	   no	   significant	   differences	   in	   activity	   levels	   between	   drug-­‐naïve	   mice	   and	   mice	  administered	   with	   0.2	   mg/kg	   buprenorphine	   or	   50	   mg/kg	   methadone	   (F(2,	   37)=0.154,	  p>0.05,	  n.s.).	  	  
Total	  distance	  traveled	  post-­‐quinpirole	  Fig	  3b	  presents	  the	  results	  for	  the	  total	  distance	  traveled	  (%	  from	  baseline)	  during	  the	  120	  minutes	   following	   treatment	   with	   quinpirole.	   	   Univariate	   Analysis	   of	   Variance	   revealed	  significant	   differences	   in	   the	   locomotor	   response	   to	   quinpirole	   between	   animals	   treated	  with	   the	   various	   drugs	   (F(2,	   28)=18.53,	   p<0.0001).	   Post	   hoc	   comparison	   revealed	   no	  significant	   differences	   in	   quinpirole-­‐induced	   suppression	   of	   activity	   level	   between	   drug-­‐naïve	  mice	   (i.e.	   saline-­‐injected	  mice)	  and	  mice	   treated	  with	  0.2	  mg/kg	  buprenorphine.	   In	  14	  
	   	   	  	   	  
	  	  
comparison,	   a	   significant	   difference	   was	   observed	   between	   drug-­‐naïve	   mice	   and	   mice	  treated	  with	  50	  mg/kg	  methadone	  (p<0.05).	  	  Quinpirole	  significantly	  increased	  the	  activity	  levels	  of	  methadone-­‐treated	  animals	   in	  comparison	  to	  the	   locomotor	  activity	  of	   the	  drug-­‐naïve	  animals.	  	  	  	  
Temporal	  analysis	  post-­‐vehicle	  Temporal	   analysis	   was	   computed	   using	   the	   distance-­‐traveled	   scores	   during	   5	   minute	  intervals	   of	   the	   120	   minutes	   post-­‐vehicle	   injection	   as	   presented	   in	   figure	   4a.	   Two-­‐way	  repeated-­‐measure	  ANOVA	  revealed	  a	  main	  effect	  of	  time	  (F(23,	  851)=13.82,	  p<0.0001),	  but	  no	   significant	   main	   effect	   of	   treatment	   (F(2,	   37)=0.68,	   p>0.05,	   n.s.)	   and	   no	   significant	  interaction	  between	   treatment	   and	   time	   (F(46,	   851)=1.22,	   p>0.05,	   n.s.).	  Reduced	  activity	  was	   observed	   for	   all	   treatment	   groups	   as	   the	   experiment	   proceeded.	   However,	   no	  differences	   in	   their	   activity	   levels	   were	   observed	   between	   drug-­‐naïve	   mice	   and	   mice	  administered	  with	  0.2	  mg/kg	  buprenorphine	  or	  50	  mg/kg	  methadone.	  	  	  
Temporal	  analysis	  post-­‐quinpirole	  Figure	   4b	   presents	   the	   temporal	   analysis	   following	   treatment	  with	   quinpirole.	   Two-­‐way	  repeated-­‐measure	  ANOVA	  revealed	  a	  main	  effect	  of	   time	  (F(23,	  644)=13.36,	  p<0.0001),	  a	  main	  effect	  of	  treatment	  (F(2,	  28)=	  23.06,	  p<0.0001),	  and	  a	  significant	  interaction	  between	  treatment	   and	   time	   (F(46,	   644)=11.95,	   p<0.0001).	   Post	   hoc	   comparison	   revealed	   no	  differences	   in	   quinpirole-­‐induced	   suppression	   of	   activity	   level	   between	   drug-­‐naïve	  mice	  (i.e.	  saline-­‐injected	  mice)	  and	  mice	  treated	  with	  0.2	  mg/kg	  buprenorphine.	  In	  comparison,	  a	  significant	  difference	  was	  observed	  between	  drug-­‐naïve	  mice	  and	  mice	   treated	  with	  50	  15	  
	   	   	  	   	  
	  	  
mg/kg	  methadone	  (p<0.05).	  Starting	  at	  10	  minutes	  following	  quinpirole	  treatment	  until	  the	  end	   of	   the	   testing	   period,	   significant	   differences	  were	   observed	   between	   drug-­‐naïve	   and	  methadone-­‐treated	  animals	   in	  their	   locomotor	  response	  to	  quinpirole	  throughout	  each	  of	  the	  5	  minute	  interval	  periods.	  	  Specifically,	  the	  methadone-­‐treated	  animals	  showed	  a	  sharp	  increase	   in	   locomotor	   activity	   10	  minutes	   after	   quinpirole	   administration,	   followed	   by	   a	  steady	   increase	   in	   locomotor	   activity	   for	   the	   remaining	   100	   minutes.	   	   At	   120	   minutes	  following	   quinpirole	   administration,	   the	   methadone-­‐treated	   animals	   reached	   an	   activity	  level	  approximately	  350%	  of	  baseline,	  while	  the	  buprenorphine	  and	  saline-­‐treated	  animals	  reached	  an	  activity	  level	  slightly	  above	  baseline.	  	  	  	  
Plasma	  levels	  of	  buprenorphine	  and	  methadone	  Following	   six	   days	   of	   oral	   administration	   of	   0.2	   mg/kg	   buprenorphine,	   a	   peak	   plasma	  concentration	   of	   7.6	   ±	   0.8	   ng/ml	   was	   observed	   2	   hours	   after	   the	   last	   dose	   of	  buprenorphine,	  as	  presented	   in	   figure	  5a.	  Following	  six	  days	  of	  oral	  administration	  of	  50	  mg/kg	  methadone	  a	  peak	  plasma	  concentration	  of	  133	  ±	  28	  ng/ml	  was	  observed	  6	  hours	  after	  the	  last	  dose	  of	  methadone,	  as	  presented	  in	  figure	  5b.	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CHAPTER IV 
 
CONCLUSIONS 
 
This study provides evidence that buprenorphine and methadone affect the locomotor response to 
a D2/D3 dopamine receptor agonist in differing ways.  Quinpirole, a D2/D3 receptor agonist, 
reduced locomotor activity in drug-naïve (saline-injected) adolescent mice, lasting for the entire 
120 minute session.  This response is consistent with literature that provides evidence that the 
suppressive effect of quinpirole on motor activity is pronounced in mice12.  Our results show that 
buprenorphine-treated animals showed a response to quinpirole similar to the response seen in 
control drug-naïve animals.  That is, no effects on the response to quinpirole were seen two hours 
or three days following final treatment of buprenorphine.  In contrast, animals treated with 
methadone showed an enhanced locomotor response after an initial suppression when 
administered quinpirole.  This response was much greater in the animals receiving quinpirole 
two hours following final treatment of methadone, as opposed to three days later.  This suggests 
that methadone itself and not the withdrawal effects, is modifying the D2/D3 receptor-signaling 
system.    
 
The ability for quinpirole to reduce locomotor activity has been suggested to be due to the 
attenuation of dopamine release13.  This effect at the presynaptic neuron is mediated by its 
activity specifically at the short isoform of the D2 dopamine receptor14,15.   In contrast, the motor 
activating effect of quinpirole is thought to be mediated by D2L/D3 postsynaptic receptors16,17.  
In our experiments, quinpirole-induced suppression of the locomotor response was still observed 
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in the methadone-treated animals in the first 10 minutes. This suggests that the presynaptic D2 
signaling or release of dopamine is not altered and the main effect is present at the postsynaptic 
D2L/D3 dopamine receptor signaling.  
 
Hyper-sensitivity to D2/D3, but not D1, dopamine receptor agonists was observed in adult rats 
undergoing morphine withdrawal18,19,20.  Recently, our group has observed that this 
supersenstivity of the D2/D3L postsynaptic receptor signaling is greatly increased in adolescents 
as compared to adults following administration of morphine21.  This study extends those results 
and demonstrates that other opioids, such as methadone, have disturbing effects on the D2L/D3 
postsynaptic receptor signaling. In addition, these studies suggest that different exposure to 
different opioids (morphine and methadone vs. buprenorphine) carries different risks in altering 
the dopaminergic system of adolescent populations. Furthermore, this study suggests that the 
enhanced effect in adolescents is probably a direct effect of opioid exposure, rather than the 
effect of withdrawal, due to the fact that there was more of an effect observed two hours 
following the last methadone administration when compared to the three day withdrawal 
animals. 
 To	  confirm	  that	  the	  doses	  of	  buprenorphine	  and	  methadone	  used	  in	  this	  study	  are	  within	  the	  range	  used	  clinically	  in	  human	  ,	  the	  plasma	  levels	  were	  recorded	  in	  the	  mice	  2,	  6,	  and	  24	   hours	   following	   the	   last	   administration	   of	   0.2	   mg/kg	   buprenorphine	   and	   50	   mg/kg	  methadone.	   	   The	   dosage	   of	   sublingual	   buprenorphine	   for	   adults	   recommended	   by	   the	  American	   Psychiatric	   Association	   for	   maintenance	   treatment	   of	   opioid-­‐dependent	  individuals,	  ranges	  from	  2	  to	  32	  mg,	  daily	  to	  3	  times	  a	  week.	  A	  similar	  range	  of	  4	  to16	  mg	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tablets	   are	   reported	   for	   the	   treatment	   of	   adolescents22.  Buprenorphine	  plasma	   levels	   in	  male	   patients	   maintained	   on	   16	   mg	   sublingual	   tablets	   was	   recorded	   to	   be	   roughly	   40	  ng×h/ml	   over	   a	   24	   hour	   period,	   reaching	   a	   maximum	   plasma	   concentration	   of	   about	   5	  ng/ml	  1.2	  hours	  after	  administration23.	  	  	  A	  wide	  range	  of	  oral	  methadone	  doses	  are	  used	  in	  patients,	   with	   the	   recommendations	   generally	   ranging	   from	   20-­‐100	   mg	   daily.	   A	   similar	  range	  was	  also	  used	  for	  clinical	  studies	  in	  adolescents,	  with	  an	  average	  maintenance	  dose	  of	  approximately	  50	  mg22.	  Therapeutic	  methadone	  plasma	  levels	  range	  between	  100-­‐1000	  ng/ml,	   with	   studies	   also	   showing	   that	   plasma	   levels	   exceeding	   200	   ng/ml	   are	   usually	  required	  for	  effectiveness.	  	  	  A	  plasma	  range	  of	  400-­‐500	  ng/ml	  is	  recommended	  for	  optimal	  therapeutic	  efficiency.	  	  Based	  on	  these	  studies,	  the	  plasma	  levels	  of	  the	  methadone-­‐treated	  animals	  were	  determined	   to	  be	   lower	   than	   that	   of	   plasma	   levels	   in	   a	  human	   therapeutic	  dose.	   	   Therefore,	   the	   enhanced	   locomotor	   response	   observed	   in	   the	   methadone-­‐treated	  animals	  was	  not	   a	   result	   of	   an	  overly	  high	  dose	  of	  methadone;	   rather	   these	   effects	  were	  seen	   at	   suboptimal	   doses.	   	   This	   suggests	   that	   the	   D2/D3	   receptor	   signaling	   system	   is	  altered	   even	   at	   low	   plasma	   levels	   of	   methadone.	   	   The	   plasma	   levels	   following	  administration	  of	  0.2	  mg/kg	  buprenorphine,	  however,	  were	  shown	  to	  be	  higher	  than	  what	  is	  expected	  from	  a	  human	  therapeutic	  dose.	  	  This	  suggests	  that	  the	  negligible	  effect	  seen	  at	  the	  D2/D3	  postsynaptic	  receptor	  is	  not	  due	  to	  a	  suboptimal	  dose	  of	  buprenorphine.	  	  	  	  Disruption	   of	   the	   dopamine	   receptor	   signaling	   may	   have	   long	   term	   effects,	   specifically	  involving	  the	  use	  of	  opioids.	  	  The	  D2	  dopamine	  receptors	  are	  important	  in	  the	  reinforcing	  properties	   associated	  with	  morphine24,	   and	   also	   in	  mediating	   drug-­‐seeking	   behaviors	   in	  mice25	  and	  rats26	  undergoing	  morphine	  withdrawal.	   	  The	  D3	  dopamine	  receptor	  has	  been	  19	  
	   	   	  	   	  
	  	  
demonstrated	   to	   play	   a	   role	   in	   opioid	   sensitization27,28	  and	   reward28,29,30.	   	   In	   addition	   to	  affecting	  opioid	  abuse,	  there	  are	  many	  other	  possible	  implications	  involved	  with	  disrupting	  the	  D2/D3	  dopamine	   receptors.	   It	   is	   suggested	  D2	   receptor	  genes	  may	  play	  a	   role	   in	   the	  abuse	  of	   various	   illicit	  drugs	  and	  alcoholism31,32,33.	   	   The	  pathophysiology	  of	   affective	   and	  psychotic	   disorders	   have	   also	   shown	   to	   potentially	   be	  mediated	   by	   the	   D2/D3	   receptor	  system34,35,36,37.	  	  	  As	  demonstrated	  in	  this	  study,	  mice	  treated	  with	  methadone	  exhibited	  supersensitivity	  to	  a	  D2/D3	   dopamine	   receptor	   agonist,	   but	   this	   effect	   was	   not	   present	   in	  mice	   treated	   with	  buprenorphine.	   Therefore,	   it	   is	   suggested	   that	   adolescents	   exposed	   to	   methadone	   may	  exhibit	  markedly	  robust	  disturbances	  of	  the	  D2/D3	  receptor	  signaling.	  Due	  to	  the	  fact	  that	  the	   dopaminergic	   system	   is	   heavily	   involved	   in	   the	   pathophysiology	   of	   many	   mental	  illnesses,	  this	  study	  suggests	  that	  extra	  care	  must	  be	  taken	  when	  contemplating	  treatment	  of	   adolescents	   with	   this	   drug	   in	   an	   opioid	   dependence	   application	   as	   well	   as	   a	   pain	  management	  application.	  In	  contrast	  to	  methadone,	  buprenorphine	  appears	  to	  disrupt	  the	  D2/D3	   dopamine	   receptor	   signaling	   in	   adolescents	   less.	   Thus,	   these	   results	   also	   suggest	  that	  different	  opioids	  carry	  different	  risks	  in	  altering	  the	  highly	  sensitive	  neurochemistry	  of	  the	  adolescent	  brain,	  especially	  at	  the	  D2/D3	  receptor	  level.	  Although	  this	  study	  indicates	  that	  buprenorphine	  might	  be	  safer	  to	  use	  than	  other	  opioids	  for	  treatment	  in	  adolescents,	  cross-­‐sensitization	  may	  develop	  between	  various	  opioids.	  Therefore,	  it	  is	  possible	  that	  the	  effects	  of	  buprenorphine	  may	  differ	  in	  opioid-­‐dependent	  adolescents	  as	  compared	  to	  drug-­‐naïve	   adolescents.	   Thus,	   further	   studies	   need	   to	   be	   conducted	   to	   examine	   the	   effect	   of	  buprenorphine	   in	  adolescents	   that	  are	  previously	  exposed	   to	  other	  opioids	   (either	   in	   the	  20	  
	   	   	  	   	  
	  	  
course	  of	  treatment	  or	  recreationally).	  It	  is	  also	  possible	  that	  the	  level	  of	  cross-­‐sensitization	  will	  differ	  between	  buprenorphine	  and	  various	  opioids.	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FIGURES	  
 
Figure 1 Mice were orally administered buprenorphine (0.1, 0.2 or 0.4 mg/kg) or methadone 
(25, 50, or 100 mg/kg) for 6 days. Three days after the final injection, their response to vehicle 
(A) or 10 mg/kg quinpirole (B) was tested. Results are presented as mean ± SEM of the total 
distance traveled scores (% from baseline) in the 120 minutes after administration of vehicle or 
quinpirole. (*) indicates a significant difference from saline-treated mice (p<0.05, Bonferroni); 
(§) indicates a significant difference from saline-treated mice (p<0.05, LSD).     
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Figure 2 Mice were orally administered buprenorphine (0.1, 0.2 or 0.4 mg/kg; A and C) or 
methadone (25, 50, or 100 mg/kg; B and D) for 6 days. Three days following the last injection, 
their response to vehicle (A and B) or 10 mg/kg quinpirole (C and D) was tested. Results are 
presented as mean ± SEM of the total distance traveled scores (% from baseline) for each 5 
minute interval during the 30 minute baseline and 120 minutes after administration of vehicle or 
quinpirole. Each time point represents the 5 minute interval immediately preceding that time. 
Quinpirole was administered at t=0. Significant differences in the locomotor response to 
quinpirole between drug-naïve mice and mice treated with the various doses of methadone were 
observed in multiple 5 minute interval periods during the 120 minutes post-quinpirole (p<0.05, 
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Bonferroni). However, these post hoc contrasts are not presented to maintain the simplicity of the 
figure. 
	  
Figure 3 Mice were orally administered 0.2 mg/kg buprenorphine or 50 mg/kg methadone for 6 
days. Two hours after the final dose, their response to vehicle (A) or 10 mg/kg quinpirole (B) 
was tested. Results are presented as mean ± SEM of the total distance traveled scores (% from 
baseline) in the 120 minutes after administration of vehicle or quinpirole. (*) indicates a 
significant difference from saline-treated mice (p<0.05, Bonferroni).     	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Figure	  4	  Mice	  were	  orally	  administered	  0.2	  mg/kg	  buprenorphine	  or	  50	  mg/kg	  methadone	  for	   6	   days.	   Two	   hours	   after	   the	   last	   dose,	   their	   response	   to	   vehicle	   (A)	   or	   10	   mg/kg	  quinpirole	   (B)	   was	   tested.	   Results	   are	   presented	   as	   mean	   ±	   SEM	   of	   the	   total	   distance	  traveled	  scores	  (%	  from	  baseline)	  for	  each	  5	  minute	  interval	  during	  the	  30	  minute	  baseline	  and	  120	  minutes	  after	  administration	  of	  vehicle	  or	  quinpirole.	  Each	  time	  point	  represents	  the	  5	  minute	  interval	  immediately	  preceding	  that	  time.	  Quinpirole	  was	  administered	  at	  t=0.	  In	  each	  5	  minute	   interval	  period	  from	  t=10	  until	   the	  end	  of	  the	  testing	  period,	  significant	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differences	   were	   observed	   between	   drug-­‐naïve	   and	   methadone-­‐treated	   animals	   in	   their	  locomotor	  response	  to	  quinpirole	  (p<0.05,	  Bonferroni). 	  
	  
Figure	  5	  Mice	  were	  orally	  administered	  0.2	  mg/kg	  buprenorphine	  or	  50	  mg/kg	  methadone	  for	  6	  days.	  Plasma	  levels	  of	  buprenorphine	  (A)	  and	  methadone	  (B)	  were	  examined	  two,	  six	  and	  24	  hours	  after	  the	  last	  administration.	  Results	  are	  presented	  as	  mean	  ±	  SEM.	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